Biotech

Themenbereich / / Biotech


Sortiere PresseMitteilungen nach: Titel (A\D) Datum (A\D)

Seiten sind aktuell sortiert nach: Datum (erst neue PresseMitteilungen)

Angle PLC: Total Voting Rights and Covington Subscription

GUILDFORD, SURREY -- (Marketwired) -- 11/16/17 -- Angle PLC (OTCQX: ANPCY) (AIM: AGL)ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, further to the announcement of 5 October 2017, 4,579,169 new ordinary shares of 10 pence each in the Company ("Ordinary Shares") were admitted to trading on AIM at 8.00 a.m. today ("Covington Admission"). These Ordinary Shares were issued pursuant to the Covington Subscription and Lock-in Deed ("Covington Subscription Shares"). Pursuant to the Covington Subscription and Lock-in Deed, Covington ...

16.11.2017

Trillium Announces Private Placement

TORONTO, ONTARIO -- (Marketwired) -- 11/15/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has entered into subscription agreements for the sale of 1,950,000 common shares and 400,000 Series II non-voting convertible first preferred shares at a price of U.S.$8.50 per share, in a non-brokered private placement for gross proceeds of U.S.$19,975,000.Net proceeds from the private placement will be used to continue the development of TTI-621 in hematologic canc ...

15.11.2017

Ceapro Reports 2017 Third Quarter Business Update and Financial Results

EDMONTON, ALBERTA -- (Marketwired) -- 11/15/17 -- Ceapro Inc. (TSX VENTURE: CZO) ("Ceapro" or the "Company") a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and nine-month periods ended September 30, 2017 and provided an overview of recent operational highlights.Financial Highlights for the Third Quarter 2017"As previously announced, we have increased our investments in our technologies as well as accelerated R&a ...

15.11.2017

Theratechnologies Announces Decision by the FDA to Extend the Ibalizumab Review Period to April 3, 2018

MONTREAL, QUEBEC -- (Marketwired) -- 11/13/17 -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) announced that it was notified today by its partner, TaiMed Biologics, Inc. ("TaiMed"), that the U.S. Food and Drug Administration ("FDA") will extend its review of the Biologics License Application ("BLA") for ibalizumab. In a notice received today by TaiMed from the FDA, the Prescription Drug User Fee Act ("PDUFA") target action date has been extended to April 3, 2018. The three-month extension period is the FDA's standard extension period.On Oc ...

14.11.2017

Trillium Therapeutics' TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting

TORONTO, ONTARIO -- (Marketwired) -- 11/13/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new preclinical and clinical data from ongoing Phase 1 a/b trials for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented this weekend at the Society for Immunotherapy of Cancer 32nd Annual Meeting in National Harbor, Maryland USA.Poster Presentation P42: The checkpoint inhibitor TTI-621 (SIRPalphaFc) stimulates innate and adaptive immune responses in patien ...

13.11.2017

Trillium Therapeutics Reports Third Quarter 2017 Financial and Operating Results

TORONTO, ONTARIO -- (Marketwired) -- 11/10/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the nine months ended September 30, 2017."Our strategy of running intravenous and intratumoral signal-seeking Phase 1 trials of TTI- 621 in multiple indications gives us the best opportunity to identify malignancies where we can further focus our clinical efforts," said Dr. Niclas Stiernholm, Trillium's Chief Executive Officer. "We ar ...

10.11.2017

Bradmer Announces Third Quarter 2017 Financial and Operational Results

TORONTO, ONTARIO -- (Marketwired) -- 11/06/17 -- Bradmer Pharmaceuticals Inc. (NEX: BMR.H) ("Bradmer" or the "Company") today announced its third quarter 2017 financial results.Financial ResultsAmounts in US dollars, unless specified otherwise, and results prepared in accordance with International Financial Reporting Standards ("IFRS").For the three months ended September 30, 2017, Bradmer recorded a net loss of $36,000 or $0.002 per common share based on the weighted average outstanding shares of 19,659,726 during the three month period, compared to a net loss ...

06.11.2017

Tauriga Sciences, Inc. Fully Retires $45,000 USD Face Value 8.00% Convertible Debenture Issued to GS Capital Partners LLC on April 27, 2017

NEW YORK, NY -- (Marketwired) -- 11/06/17 -- Tauriga Sciences, Inc. (OTC PINK: TAUG) ("Tauriga" or the "Company"), engaged in building of businesses in the life sciences space, today announced that is has retired the $45,000 USD face value 8.00% convertible debenture (the "Note") held by GS Capital Partners, LLC ("GS Capital"). This Note was issued by the Company on April 27, 2017. Accordingly, this debt will be removed from the Company's balance sheet.This Note was retired exclusively through a one-time conversion exercised by GS Capital on Novemb ...

06.11.2017

Trillium Therapeutics to Present at Upcoming Scientific Conferences

TORONTO, ONTARIO -- (Marketwired) -- 11/06/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company's programs and progress at several upcoming scientific conferences.Society for Immunotherapy of Cancer 32nd Annual MeetingPresenter: Lisa Johnson, Ph.D., Trillium Research ScientistTitle: The checkpoint inhibitor TTI-621 (SIRPaFc) stimulates innate and adaptive immune responses in patients with hematologic ...

06.11.2017

Angle PLC: Holding(s) in Company

GUILDFORD, SURREY -- (Marketwired) -- 11/06/17 -- Angle PLC (AIM: AGL) (OTCQX: ANPCY)(AIM:AGL OTCQX:ANPCY)Contacts: RNS Customer Services 0044-207797-4400 ...

06.11.2017

Angle PLC: Holding(s) in Company

GUILDFORD, SURREY -- (Marketwired) -- 11/06/17 -- Angle PLC (AIM: AGL) (OTCQX: ANPCY)(AIM:AGL OTCQX:ANPCY)Contacts: RNS Customer Services 0044-207797-4400 ...

06.11.2017

Angle PLC: Holding(s) in Company

GUILDFORD, SURREY -- (Marketwired) -- 11/06/17 -- Angle PLC (OTCQX: ANPCY) (AIM: AGL)(AIM:AGL OTCQX:ANPCY)Contacts: RNS Customer Services 0044-207797-4400 ...

06.11.2017

Angle PLC: Holding(s) in Company

GUILDFORD, SURREY -- (Marketwired) -- 11/02/17 -- Angle PLC (AIM: AGL) (OTCQX: ANPCY)Contacts: RNS Customer Services 0044-207797-4400 ...

02.11.2017

Angle PLC: Completion of Fundraising and Acquisition

GUILDFORD, ENGLAND -- (Marketwired) -- 11/01/17 -- Angle PLC (AIM: AGL) (OTCQX: ANPCY)ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that further to the announcement of 30 October 2017 and General Admission earlier today, the Fundraising and Acquisition of certain assets of Axela Inc. is now complete.Capitalised terms not otherwise defined in this announcement shall have the same meaning ascribed to such terms in the announcement entitled "Acquisition and Fundraising" released on 5 October 2017 unless the context requires otherwise.ANG ...

01.11.2017

ANGLE plc: Result of AGM Location

GUILDFORD, SURREY -- (Marketwired) -- 10/31/17 -- ANGLE plc (AIM: AGL) (OTCQX: ANPCY)AIM:AGL OTCQX:ANPCYANGLE plc (AIM: AGL) (OTCQX: ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed.ANGLE is a world-leading liquid biopsy company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.ANGLE's cell separation te ...

31.10.2017

Sermonix Pharmaceuticals Announces Recent Closure of $4.2 Million Seed Preferred Equity Bridge to Fund Operations, Prepare for Phase II Breast Cancer Study

COLUMBUS, OH -- (Marketwired) -- 10/31/17 -- Sermonix Pharmaceuticals LLC, a privately held biotechnology company focused on the development and commercialization of female-specific oncology products, today announced its recent completion of a $4.2 million Seed Preferred Equity Bridge financing round to fund ongoing operations and prepare for entry of investigational drug lasofoxifene into a Phase II clinical trial in Estrogen Receptor Positive (ER+) Metastatic Breast Cancer.Lasofoxifene, a newer-generation selective estrogen receptor modulator (SERM), is one of the most well-studied drugs in ...

31.10.2017

ANGLE plc: Result of General Meeting

GUILDFORD, ENGLAND -- (Marketwired) -- 10/30/17 -- ANGLE plc (AIM: AGL) (OTCQX: ANPCY)AIM:AGL OTCQX:ANPCYANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that further to the announcement of 5 October 2017, the Resolutions put to Shareholders at the General Meeting earlier today were duly passed. Completion of the Acquisition, Placing and General Subscription are conditional on admission of the EIS/VCT Placing Shares becoming effective at 8.00 a.m. on 31 October 2017 ("EIS/VCT Admission") and Admission of the General Placing Shares and Ge ...

30.10.2017

Microbix Completes Second Tranche of Brokered Private Placement

TORONTO, ONTARIO -- (Marketwired) -- 10/27/17 -- Microbix Biosystems Inc. (TSX: MBX) ("Microbix" or the "Company"), a developer and marketer of biological products and technologies, announces that it has completed a second and final tranche of the brokered private placement financing announced on October 19, 2017. An aggregate of 7,784,500 Units were issued in the first tranche for gross proceeds of $2.33 million. Microbix has now closed a second tranche of private placement financing for further gross proceeds of $1.17 million, resulting in the issue of 3,882,133 more Un ...

27.10.2017

Ceapro Inc. Announces the Launch of its Proprietary Line of Cosmeceutical Products, JUVENTE

EDMONTON, ALBERTA -- (Marketwired) -- 10/26/17 -- - Successful execution of Juvente(DC) Inc. acquisition marks an important step in Ceapro's strategic market diversification business plan -- New anti-aging skin care product line represents $5B market opportunity and utilizes Ceapro's active ingredients beta glucan and avenanthramides -(TSX VENTURE: CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its entry into the e ...

26.10.2017

Angle PLC: Total Voting Rights

GUILDFORD, SURREY -- (Marketwired) -- 10/26/17 -- Angle PLC (OTCQX: ANPCY) (AIM: AGL)AIM:AGL OTCQX:ANPCYANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, following the announcement of 12 October 2017, 7,481,570 New Ordinary Shares have been issued pursuant to the Further Subscription. Following completion of the Admission of the Further Subscription Shares, the total number of Ordinary Shares in issue is 82,297,344.The figure of 82,297,344 should be used by shareholders as the denominator for the calculations by which they will determine if they are requi ...

26.10.2017


Seite 1 from 253:  1 2  3  4  5  .. » 253





Firmen die firmenpresse.de für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H


I J K L M N O P Q R S T U V W X Y Z